Biofrontera Inc. announced the launch of the RhodoLED XL, a new red-light-emitting LED lamp approved by the US Food and Drug Administration (FDA) in combination with Ameluz (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy of actinic keratoses of mild-to-moderate severity on the face and scalp.

With state-of-the-art engineering, robust but sleek construction, and an intuitive user interface the lamp is designed to be simple to maneuver and able to accommodate various patient treatment positions in order to optimize ease of use.

Ameluz is approved by the FDA in combination with either member of the RhodoLED lamp family. The introduction of the RhodoLED XL provides the option to illuminate a larger area in a single on-label Ameluz photodynamic therapy treatment. Additional features include positioning sensors to ensure the patient receives the optimal energy delivery from the LED array.

“The XL lamp's advanced features and user-friendly design will undoubtedly set a new standard in photodynamic therapy,” Biofrontera CEO Hermann Luebbert said in a press release.

Cleaver Dermatology in Missouri and Georgia was the first practice to have the RhodoLED XL lamp installed.

“The advanced features and versatility of this device represent a considerable upgrade on what has been available until now and will allow us to provide our patients with the highest standard of care,” Dr. David Cleaver said in the press release.